about
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers.Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis.Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population.Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement.Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease.Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.The Italian MSUS Study Group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatology.Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature.Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features.A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis.The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis.The concept of early systemic sclerosis following 2013 ACR\EULAR criteria for the classification of systemic sclerosis.Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study.The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.Hashimoto's thyroiditis is associated with peripheral lymphocyte activation in patients with systemic sclerosis.Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis.Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment.Diffusion and applications of musculoskeletal ultrasound in Italian Rheumatology Units.Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study.[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability]Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis.Tissue Doppler imaging in systemic sclerosis: a 3-year longitudinal study.Remission in early, aggressive rheumatoid arthritis: a multicentre prospective observational Italian study ARPA (Artrite Reumatoide Precoce Aggressiva).Early onset neutropenia after mycophenolate mofetil in systemic sclerosis.Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension.Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis.Apolipoprotein A-I-dependent cholesterol esterification in patients with rheumatoid arthritis.Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy.Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study.Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis.Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence.Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters.Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population.Cell-free DNA in the plasma of patients with systemic sclerosis.
P50
Q33766384-BD444733-8DCA-45D6-9418-BF7E4F335FD3Q34559161-D4D770B9-E2C9-4360-9387-051F37A8CC35Q34684413-AE32ABE1-8022-48AF-B40C-BED283CCF7ADQ35577317-4CDAE6E3-1800-43E5-9E97-6EB9CA92A9D3Q35759176-421834A7-B437-4900-BD5C-96B30E0172B0Q36633414-8F8D4479-E997-473D-86A0-43510B41C9D4Q36687460-1CC91FB2-ED1E-4A02-8C63-1C2648359CC2Q37690559-A2918482-8738-4416-9A2F-078A856875B3Q38160306-50D041AD-F6DE-4473-AABA-6EC4979E1381Q38163917-62ED1630-E3DB-4DE7-B445-72523FC6D349Q38245569-75B9239C-352F-498D-8BCB-7DC4082FFCD1Q39938323-88723E22-4DC4-434A-B304-4D191C1A1E9FQ39955870-299DA2A8-6018-4FFB-A26E-78498B2248E8Q40099352-E706D6B5-8F72-4A9E-A22F-DAAF3AD00069Q40183753-1CEEEB57-F44E-4C50-BEC8-19B686F03E82Q40218254-B968DD76-7400-404E-8CFC-1ED7998C2D5FQ40462327-DF7AD578-0581-4C35-A7B7-B63294CCB947Q42476030-7577BF61-02AC-4FEF-8800-489AFA9862C7Q42505740-03F31FDB-6D88-4250-97E3-6C1C38A1AD81Q42615760-4A2263C1-1C74-42F8-8EF2-F705F499DEC3Q42983684-58B2D1AF-1D94-43D0-9A4F-A1AE0511BCADQ44372617-0F86FD64-0BA8-4AC3-8D3E-5A3F22932680Q44425363-F13BC7DA-8D29-433A-A0E1-1D60988AC32CQ45219248-331B871E-D1DB-4714-88A1-B9B00C3998B8Q45279700-013461BC-67ED-4599-B62B-AD24ECE6A4DAQ45364555-6EB3D6CB-5B48-4E12-95E5-22E1136A617EQ45926888-33BA9199-E892-4E57-BCC8-249380EF685FQ46106790-A7A43551-1B04-4396-B81E-9F9F241CB3BAQ46377829-18555C5E-F30E-435A-9701-D3E1C08222E6Q46441368-6D93E353-2379-4B66-98D5-C99A861DAFBEQ46452306-DE42A6E7-6904-4965-9732-C299F16775ADQ46987453-8FF5286C-D54A-4C73-AEC6-5763A5EA3454Q47318191-BF80EEE0-3BD2-4503-A88E-C16B967D5245Q47967636-4CFE2253-5548-47AD-8258-3E590C42C253Q48058216-FF94CDA2-1EBE-4D26-BA21-625C6BFCB77BQ48179396-C8BBC28D-8F5F-4833-9749-3BD411719F31Q51652950-79AD27E4-D5A5-481A-B4B9-86AB7C7C5F19Q51693090-15E52AD7-0324-44A6-9567-35D922927B86Q54421707-5F42AB4C-375E-4177-A380-6CE9C82A97DCQ54469768-0A8EECC3-A433-4303-9507-6344E75EDDF0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giovanna Cuomo
@ast
Giovanna Cuomo
@en
Giovanna Cuomo
@es
Giovanna Cuomo
@nl
Giovanna Cuomo
@sl
type
label
Giovanna Cuomo
@ast
Giovanna Cuomo
@en
Giovanna Cuomo
@es
Giovanna Cuomo
@nl
Giovanna Cuomo
@sl
prefLabel
Giovanna Cuomo
@ast
Giovanna Cuomo
@en
Giovanna Cuomo
@es
Giovanna Cuomo
@nl
Giovanna Cuomo
@sl
P106
P21
P31
P496
0000-0002-4292-3589